Cyclin-dependent kinase 4–Cyclin D1 complex (CDK4–Cyclin D1) (CDK4–Cyclin D1)

The Cyclin-dependent kinase 4 (CDK4)–Cyclin D1 complex is a pivotal enzyme assembly that regulates the G1 to S phase transition of the eukaryotic cell cycle (UniProt: P11802, P24385). CDK4 functions as the catalytic subunit, while Cyclin D1 acts as the essential regulatory subunit that activates the kinase upon binding (NCBI: PMC6163035). The primary substrate of this complex is the Retinoblastoma (Rb) protein; its phosphorylation by CDK4–Cyclin D1 releases E2F transcription factors to initiate DNA synthesis (StatPearls: NBK562274). Aberrant activation of this pathway, frequently via CCND1 gene amplification or p16INK4a loss, is a common driver in many cancers, including breast cancer and mantle cell lymphoma. Therapeutic targeting of the complex involves small-molecule inhibitors that compete with ATP for the kinase's active site. Drugs such as palbociclib, ribociclib, and abemaciclib have been successfully developed to inhibit this complex, significantly improving outcomes in metastatic breast cancer (FDA: Ibrance, Kisqali, Verzenio). Clinical use of these inhibitors requires monitoring for biomarkers like Rb expression, as the presence of functional Rb is typically necessary for drug efficacy. Common safety concerns associated with targeting this complex include hematologic toxicities like neutropenia and systemic effects such as fatigue and diarrhea.

Other names

CDK4-CCND1 complexCyclin D1-CDK4 complexCCND1-CDK4CDK4-Cyclin D1 complexCDK4/Cyclin D1

Selective inhibition of the kinase activity of the CDK4-Cyclin D complex, preventing phosphorylation of the Retinoblastoma (Rb) protein and inducing G1 cell cycle arrest (StatPearls: NBK562274).